Stoke Therapeutics, Inc. (STOK) Stock
3 of the hedge funds AlphaScala tracks reported STOK in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $16.01M. Company insiders reported 0 open-market buys and 12 sales on SEC Form 4 in the 90 days to Nov 10, 2026.
Which hedge funds own STOK?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 489K | $16.01M | +298% |
| Millennium Management Israel Englander | 261K | $8.54M | -45% |
| D.E. Shaw David Shaw | 58K | $1.89M | +16% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Stoke Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 2, 26 | Ticho Barry | CHIEF MEDICAL OFFICER | SELL | 7.0K | $185K |
| Nov 2, 26 | Ticho Barry | CHIEF MEDICAL OFFICER | SELL | 200 | $5K |
| Oct 2, 26 | Allan Jonathan | GENERAL COUNSEL & CORP SEC | SELL | 627 | $17K |
| Oct 1, 26 | Ticho Barry | CHIEF MEDICAL OFFICER | SELL | 1.1K | $27K |
| Sep 1, 26 | Ticho Barry | CHIEF MEDICAL OFFICER | SELL | 3.9K | $120K |
| Sep 1, 26 | Ticho Barry | CHIEF MEDICAL OFFICER | SELL | 1.6K | $50K |
| Aug 18, 26 | Kaye Edward M. Md | Director | SELL | 11.9K | $382K |
| Aug 18, 26 | Kaye Edward M. Md | Director | SELL | 637 | $21K |
| Aug 18, 26 | Ticho Barry | CHIEF MEDICAL OFFICER | SELL | 4.5K | $145K |
| Aug 18, 26 | Ticho Barry | CHIEF MEDICAL OFFICER | SELL | 242 | $8K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →STOK price chart
Powered by TradingViewWhat does Stoke Therapeutics, Inc. do?
Stoke Therapeutics Inc. is a biotechnology company focused on developing RNA-based medicines to treat the underlying causes of severe genetic diseases. It employs its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform, which uses antisense oligonucleotides to upregulate protein expression from healthy genes, compensating for mutated copies in conditions known as autosomal dominant haploinsufficiencies. This approach targets tissues including the central nervous system, eye, kidney, and liver. The company's lead investigational medicine, zorevunersen (STK-001), addresses Dravet syndrome, a severe genetic epilepsy characterized by frequent seizures, intellectual disability, and developmental delays, with ongoing Phase 3 clinical studies in collaboration with Biogen. Additional efforts explore TANGO ASOs for autosomal dominant optic atrophy and other severe diseases. Stoke Therapeutics Inc. maintains a pipeline aimed at pioneering disease-modifying therapies. Founded in 2014 and headquartered in Bedford, Massachusetts, the company drives innovation in precision medicine for genetic disorders.